Steven S. Williamson

President and CEO at Pulmonx

Since March 15, 2024

Age

51 years

Education

Earned a Bachelor of Business Administration from the University of Massachusetts, Amherst and a Master of Business Administration from Bentley College.

Tenure

Appointed as President and CEO on March 15, 2024, and also serves as a Class II member of the Board of Directors at LUNG.

Also at Pulmonx

David Lehman

General Counsel

GBR

Geoffrey Beran Rose

Chief Commercial Officer

John McKune

Vice President, Corporate Controller

About

Steven S. Williamson is the current President and Chief Executive Officer of Pulmonx Corporation (LUNG). He assumed this role on March 15, 2024, following a successful career in the medical device industry.

Before joining LUNG, he built nearly 30 years of experience through several high-profile leadership roles, including serving as Chief Commercial Officer at Outset Medical, Inc. from November 2020 to February 2024, as well as holding pivotal positions at C.R. Bard/Becton, Dickinson and Company and Hologic, Inc..

Under his leadership at LUNG, the company has focused on expanding patient access to innovative therapies, achieving record financial results in 2024 with $83.8 million in worldwide revenue, a 22% year-over-year increase, and a 74% gross margin. His strategic direction emphasizes commercial excellence, innovative product launches, and transformative market growth.

In addition to his considerable professional accomplishments, his academic foundation, including a Bachelor of Business Administration from the University of Massachusetts, Amherst and an MBA from Bentley College, has played a key role in his strategic approach to leadership.

$LUNG Performance Under Steven S. Williamson

Past Roles

Organization	Role	Date Range	Details
C.R. Bard / Becton, Dickinson and Company (BD)	Worldwide President for the Peripheral Intervention business unit	August 2012 to November 2020 (last role ended in October 2020)	Held various roles culminating in this executive position; last role ended in October 2020
Novacept Inc.	Employee	May 2003 to August 2012	Acquired by Cytyc Corporation in March 2004
Cytyc Corporation / Hologic, Inc.	Senior Vice President and General Manager of the GYN Surgical Products Business	Approximately March 2004 to October 2007	Held various roles with increasing responsibility through the acquisition by Hologic, Inc.

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Annual Base Salary	$580,000	Payable in two equal payments per month	Subject to annual review by the Board
Reimbursement for Commuting Expenses	Reimbursed	N/A	Covers travel and California lodging/housing expenses, including a tax gross-up

Performance Compensation

Data from FY 2024

No information available on performance compensation for 2024